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This prospective study aimed to validate a previously developed ﬁrst-dose limited sampling strategy (LSS) to
predict the area under the cyclosporine concentration-versus-time curve (AUC) and to develop and then
validate an LSS to predict cyclosporine AUC at steady state. This two-center Canadian study included children
(ages .4 to 17.2 years) undergoing myeloablative allogeneic hematopoietic stem cell transplantation receiving
cyclosporine for acute graft-versus-host disease prophylaxis. There were three cohorts, each incorporating
24 AUC determinations: ﬁrst-dose LSS validation, steady-state LSS development, and steady-state LSS vali-
dation. Patients contributing data to either of the development cohorts were excluded from the corre-
sponding validation group. Cyclosporine was given every 12 hours as a 2-hour infusion. Cyclosporine AUC was
determined after administration of the ﬁrst cyclosporine dose (8 samples) and then once weekly (9 samples)
until engraftment. Steady-state LSSs were developed using stepwise multiple linear regression. An LSS was
considered to provide an acceptable estimate of AUC if the lower limit of the 95% conﬁdence limit (CL) of the
intraclass coefﬁcient was .8 or higher and both bias and precision were 15% or less. Fifty-three children age .4
to 18 years participated. Cyclosporine concentrations drawn up to 4 hours from the start of the infusion
correlated most strongly with AUC. The previously developed ﬁrst-dose LSSs and three steady-state LSSs met
criteria for acceptability. The intraclass coefﬁcients of the three-point ﬁrst-dose LSS validation cohort, three-
point steady-state LSS development cohort, and three-point steady-state LSS validation cohort were .974 (95%
CL: .941 to .988), .984 (95% CL: .965 to .993), and .993 (95% CL: .984 to .997), respectively. The three-point
ﬁrst-dose (2, 6, and 8 hours) and steady-state (2, 2.5, and 8 hours) LSSs are valid measures of cyclosporine
AUC after intravenous administration over 2 hours. Their use in a prospective evaluation of the relationship
between cyclosporine AUC and hematopoietic stem cell transplantation clinical outcomes in children is
suggested.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Acute graft-versus-host-disease (aGVHD) is the primary
cause of treatment-related mortality after hematopoietic
stem cell transplantation (HSCT) and has a great impact on
morbidity and quality of life [1]. Calcineurin inhibitors
(cyclosporine or tacrolimus) in combination with short-
course methotrexate or corticosteroids are most commonly
used for aGVHD prevention. Because inter- and intra-
individual variability in cyclosporine disposition is high,
the whole blood trough concentration (C0) is routinely used
to individualize cyclosporine doses in HSCT patients.
However, evidence to support a relationship between C0
values and aGVHD prevention is limited and highly variable.
For example, reported target C0 values range from 85 toedgments on page 422.
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12.10.031500 ng/mL [2-6]. As a result, there is no consensus regarding
the optimal target C0 range, and targets vary widely among
institutions [7].
Prevention of acute graft rejection correlates more
strongly with area under the cyclosporine concentration-
versus-time curve (AUC) than C0 in both adult and pediatric
solid organ transplant patients [8,9]. Cyclosporine dose
adjustment based on AUC rather than C0 has consequently
become the standard of care. This approach has only just
begun to be evaluated in HSCT [10-19]. Classical determina-
tion of AUC entails a large total blood sample volume, high
workload to obtain the samples, high assay costs, and
potentially a high level of patient inconvenience or distress.
Blood volume is especially a concern in pediatrics. A valid
limited sampling strategy (LSS) would facilitate large-scale
evaluations of the relationship between cyclosporine AUC
and clinical outcomes such as aGVHD prophylaxis in
pediatrics.
We described the relationship between AUC and whole
blood cyclosporine concentrations at various single timeTransplantation.
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(i.v.) cyclosporine dose given as a 2-hour infusion in 24
children undergoing HSCT [20]. Strong correlations between
AUC and each of the concentrations obtained within the ﬁrst
4 hours after the start of the infusion (2, 2.5, 3, and 4 hours)
(Spearman rho coefﬁcient ¼ .717 to .868) were observed
but only a moderate relationship (Spearman rho coef-
ﬁcient ¼ .442 to .553) between AUC and the concentrations
obtained at the remaining time points. The correlation
between C0 and AUC was moderate (Spearman rho
coefﬁcient¼ .457). Using these data, we developed an LSS for
the prediction of AUC achieved in children after adminis-
tration of the ﬁrst i.v. cyclosporine dose. An LSS for prediction
of cyclosporine AUC after steady-state cyclosporine i.v.
administration has not yet been developed.
The primary purpose of this prospective study was to
validate the LSS previously developed to estimate cyclo-
sporine AUC after the ﬁrst i.v. cyclosporine dose and to
develop and validate an LSS for use once steady state was
achieved in children undergoing HSCT. These LSSs will be
used in future studies of the relationship between HSCT
clinical outcomes and cyclosporine AUC and cyclosporine
concentrations at time points other than C0.METHODS
This study was approved by the Research Ethics Boards of both SickKids
and BC Children’s Hospital. Patients or guardians provided informed consent
and/or assent.Study Population
Patients less than 18 years of age who were undergoing allogeneic
myeloablative HSCTat either SickKids orWomen’s and Children’s Hospital of
British Columbia and who were scheduled to receive cyclosporine for
aGVHD prophylaxis were eligible to participate. Children who received
voriconazole or posaconazole within 14 days of the ﬁrst cyclosporine dose,
or at any time until engraftment, were excluded. Patients receiving ﬂuco-
nazole were included in this study because ﬂuconazole does not alter the
disposition of i.v. cyclosporine [21,22].Cyclosporine Administration, Blood Sampling, and Dose Adjustment
Cyclosporine was administered as a 120-minute (15 minutes) i.v.
infusion (including the line ﬂush) every 12 hours starting on day 3, 2,
or1 (where the day of HSCT is day 0). One lumen of a central venous access
device was used consistently for cyclosporine dose administration. Cyclo-
sporine dose adjustments were made by the clinical team caring for the
patient using the blood samples obtained for clinical care in accordancewith
the institutional target C0 concentrations (100 to 200 ng/mL).
All samples for cyclosporine concentration determination were ob-
tained from a lumen of a central venous access device not used for cyclo-
sporine administration. After the ﬁrst i.v. cyclosporine dose, blood samples
were obtained for determination of cyclosporine concentration at 2 (end of
the infusion), 2.5, 3, 4, 6, 8, 10, and 12 hours after the start of the 2-hour
infusion. Samples drawn within 10 minutes of the ideal sampling time
were acceptable.
After day 0, blood samples were obtained for determination of cyclo-
sporine concentration after the morning dose weekly on a standard day of
the week (eg, every Monday) until engraftment (absolute neutrophil
count>.5109/L on 2 consecutive measurements separated bymore than 1
day) occurred. In total, 9 blood samples per week were obtained: just before
the morning cyclosporine dose and at 2 (end of the infusion), 2.5, 3, 4, 6, 8,
10, and 12 hours after the start of the 2-hour infusion. Blood samples were
obtained weekly for no longer than 7 weeks after transplantation.Cyclosporine Assay
Whole blood cyclosporine concentrations were determined in a single
laboratory using tandem mass spectrometry. The interday coefﬁcient of
variation of this assay is 3.6% to 4.2% (WarrenWalsh, Resource Technologist,
Department of Laboratory Medicine, SickKids, personal communication,
October 27, 2009) Study samples were frozen at 20C until assayed.Data Analysis
Statistical analysis was performed using SAS Enterprise Guide (version
4.3, SAS Institute, Cary, NC) or SPSS (version 17, SPSS Inc., Chicago, IL).
A P value of .05 or less was considered to indicate statistical signiﬁcance.
Pharmacokinetics
The cyclosporine AUC achieved over the 12-hour dosing interval was
calculated using all data points (AUC-12) for all patients using non-
compartmental methods (Pharsight Phoenix WinNonLin 6.0.0.1648, St
Louis, MO). The relationship between AUC and whole blood cyclosporine
concentrations at individual time points was assessed by the Spearman rho
correlation coefﬁcient.
First-Dose LSS Validation
The previously developed ﬁrst-dose LSS [20] was validated using the
cyclosporine concentrations obtained from the ﬁrst 24 patients enrolled for
whom 8 properly timed cyclosporine concentrations were available. Each
patient’s AUC was calculated using the previously developed LSSs. Agree-
ment between the AUC-12 and the AUC calculated using each LSS was
assessed using a single-measure, one-way, random effect, intraclass coefﬁ-
cient (ICC) [23,24]. Agreement was considered to be acceptable if the lower
limit of the 95% conﬁdence limit of the ICC was .8 or higher. The extent of
agreement between AUC-12 and predicted AUC was also assessed using
Bland-Altman analysis. The limits of agreement (mean % difference 2
standard deviations, where % difference¼ 100[(AUC-12eAUC-LSS)/(mean of
AUC-12 and AUC-LSS)]) were calculated. It was not possible to determine the
clinically signiﬁcant limits of agreement a priori for cyclosporine because
the clinical signiﬁcance of AUC-12 with respect to HSCT outcomes is not yet
established. Bias (mean prediction error) and precision (root mean squared
error) of 15% or less were considered to be acceptable [25]. In summary, an
LSS was considered to provide an acceptable estimate of AUC-12 if the lower
limit of the 95% conﬁdence limit of the ICC was .8 or higher and both bias
and precision were 15% or less. The association between patient age and
percent bias of the AUC estimated by the 3-point LSS was undertaken using
linear regression analysis.
Steady-State LSS Development and Validation
Steady state was deﬁned as having been achieved once the patient had
received at least 4 consecutive, identical cyclosporine doses. The ﬁrst 24
patients enrolled for whom all 9 cyclosporine concentrations were available
at steady state constituted the development group; the second group of 24
patients enrolled for whom 9 properly timed cyclosporine concentrations
were available at steady state constituted the validation group. None of the
patients in the validation group was included in the development group.
LSSs were developed at steady state using stepwise multiple linear
regression analysis [25]. LSSs involving 5 or fewer data points were
preferred for model parsimony and clinical utility. Adjusted r2 values greater
than .9 were considered acceptable. Agreement between AUC-12 and the
AUC calculated using each steady-state LSS was assessed using ICC and
Bland-Altman analysis as described above, as were the criteria for accep-
tance of a steady-state LSS as an estimate of AUC-12. The association
between patient age and percent bias of the AUC estimated by the 3-point
LSSs was undertaken using linear regression analysis.
RESULTS
From June 2008 to March 2012, 104 patients were
screened for study eligibility. Thirty did not meet study entry
criteria, 12 declined to participate, the attending physician of
5 patients asked that they not be approached, and 3 were
missed due to logistical problems. Fifty-four patients were
enrolled; 1 later withdrew before sampling at steady state
occurred. Of the patients who enrolled, blood sampling
deviated from protocol after administration of the ﬁrst dose
in 14 patients. Furthermore, blood sampling deviated from
protocol or cyclosporine dosing never achieved steady state
in 3 and 2 patients beyond the ﬁrst cyclosporine dose,
respectively. Data from 53 children are reported here.
Demographic data relating to the study patients are pre-
sented in Table 1. It is notable that mycophenolate mofetil
was more commonly used in the steady-state validation
cohort (7 of 24 patients) compared with the other cohorts
(0 or 1 of 24 patients). Fourteen patients contributed data to
both the ﬁrst-dose LSS validation group and the steady-state
LSS development group, whereas 7 contributed data to both
Table 1
Description of patients in First Dose Development (N ¼ 24) and Validation (N ¼ 24) Cohorts and Steady-State Development (n ¼ 24) and
Validation (n ¼ 24) Cohorts
Parameter First-Dose Development
Cohort
First-Dose
Validation Cohort
Steady-State
Development Cohort
Steady-State
Validation Cohort
Mean age, yr, SD (range) 8.8  4.81 (.5-16.9) 8.8  4.89 (.4-17.2) 10.2  5.06 (.4-17.2) 9.3  3.54 (3.3-17.2)
Day of sampling (no. days after HSCT) d d 18.0  8.70 (10-39) 17.6  7.39 (4-32)
Mean cyclosporine dose
(mg/kg; SD) 1.5  .05 2.1  .57 2.3  1.28 2.5  1.57
(mg/m2; SD) NA 58.4  9.64 69.2  34.04 69.6  35.79
Number of patients
Sex (male:female) 16:8 15:9 16:8 15:9
Underlying diagnosis
ALL 8 5 4 7
AML 10 9 10 7
Other malignancies 2 2 3 3
Nonmalignancies 4 8 7 7
HSCT conditioning
Cyclophosphamide-containing 21 24 24 22
Other 3 0 0 2
GVHD prophylaxis
CSA alone 0 2 0 2
CSA þ
Methotrexate 24 13 17 11
Mycophenolate mofetil 0 1 0 7
Corticosteroid 0 6 6 4
Methotrexate þ corticosteroid 0 2 1 0
SD indicates standard deviation; NA, not available; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia.
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validation group.First-Dose LSS Validation
Table 2 illustrates that whole blood cyclosporine
concentrations drawn within the ﬁrst 4 hours from the start
of the infusion correlated strongly with AUC-12 (Spearman
rho coefﬁcient ¼ .66 to .91) Correlations with other time
points were moderate.
The four previously developed ﬁrst-dose LSS met the
criteria for acceptability (Table 3). That is, adjusted r2 was
> .9, ICC indicated good agreement, and mean bias and
precision were < 15%. In addition, Bland-Altman analysis
indicated good agreement between the AUC-12 and pre-
dicted AUC values (Table 3, Figure 1A). No signiﬁcant asso-
ciation between patient age and percent bias of the AUC
estimates was observed (adjusted r2 ¼ .0332). AUC-12 and
AUC values calculated using the LSSs are presented in Table 4.Steady-State LSS Development and Validation
The mean day of sampling relative to day 0 was
day þ18.0  8.7 and day þ17.6  7.4 in the steady-state LSS
development and validation cohorts, respectively. Whole
blood cyclosporine concentrations drawn from 2 to 4 hours
from the start of the 2-hour infusion correlatedmost strongly
with AUC-12 (Table 2; Spearman rho coefﬁcient ¼ .80609 to
.87913 [validation cohort] and .85409 to .95238 [develop-
ment cohort]). Correlations with other time points were also
signiﬁcant in both cohorts. However, although the correla-
tions were weak to moderate at time points beyond 4 hours
from the start of the 2-hour infusion in the development
cohort, correlations with AUC-12 were strong at all time
points in the validation cohort.
Three steady-state LSSs were developed that met criteria
for acceptability: the three-, four-, and ﬁve-point LSSs
(Table 3, Figure 1B). That is, ICC indicated good agreement
between the AUC-12 value and that predicted by the three-,
four-, and ﬁve-point LSSs, adjusted r2 was > .9, and bothmean bias and precision were < 15%. The Bland-Altman
analysis also indicated good agreement. When evaluated in
the validation cohort, the 3 acceptable steady-state LSSs also
met criteria for acceptability and demonstrated good agree-
ment with AUC-12 values (Table 3, Figure 1C). No signiﬁcant
association between patient age and percent bias of the AUC
estimates was observed in either cohort (adjusted
r2 ¼ .0187 [development cohort] and .0249 [validation
cohort]). AUC-12 and AUC values calculated using the LSSs
are presented in Table 4.DISCUSSION
Using complete pharmacokinetic proﬁles collected
prospectively, we developed and validated LSSs for predict-
ing AUC of cyclosporine after administration as a 2-hour i.v.
infusion to children undergoing HSCT both after the ﬁrst
dose and at steady state. Speciﬁcally, we found that a 3-point
LSS is a valid method for estimating cyclosporine AUC after
both the initial i.v. cyclosporine dose and at steady state. This
informationwill facilitate assessment of cyclosporine AUC by
clinicians and the assessment of the relationship, if any,
between cyclosporine AUC and HSCT outcomes in future
studies.
Cyclosporine dose adjustment using the trough whole
blood cyclosporine concentration (C0) remains the standard
in HSCT, although the target concentration range is highly
variable among HSCT centers as stated previously. Several
investigators have reported cyclosporine AUC in HSCT
patients after i.v. administration [3,10-14,16-19,26,27]. The
method used to calculate or estimate cyclosporine AUC was
not described in some of these reports [13], and serum rather
than whole blood concentrations (the accepted standard
matrix) were reported in another [10]. LSSs have been
developed and validated for estimation of AUC-12 in HSCT
patients older than 15 years receiving oral cyclosporine [17].
The proposed LSSs had minimal bias. Agreement between
AUC-12 and the AUC estimates generated by the LSSs was not
evaluated. Most pediatric patients receive i.v. cyclosporine
Table 2
Spearman Rho Correlation Coefﬁcients for AUC-12 and Whole Blood Cyclosporine Concentrations at Time Points after the Start of a 2-Hour Infusion
Sampling
Time (h)
First-Dose LSSValidation Cohort Steady-State LSS Development Cohort Steady-State LSS Validation Cohort
Spearman
Rho Coefﬁcient
Signiﬁcance
(Two-Tailed)
Spearman
Rho Coefﬁcient
Signiﬁcance
(Two-Tailed)
Spearman
Rho Coefﬁcient
Signiﬁcance
(Two-Tailed)
0 NA NA .43845 .0321 .80409 <.0001
2 .91324 <.0001 .87913 <.0001 .85478 <.0001
2.5 .66014 <.0004 .83652 <.0001 .95238 <.0001
3 .71739 <.0001 .80609 <.0001 .91933 <.0001
4 .90039 <.0001 .83826 <.0001 .94609 <.0001
6 .82775 <.0001 .54502 .0059 .92345 <.0001
8 .74543 <.0001 .47097 .0202 .90522 <.0001
10 .65810* <.0006 .45605 .0251 .89841 <.0001
12 .68099* <.0007 .34181* .1021 .87671 <.0001
* n ¼ 23.
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weeks later, usually after engraftment. Because achievement
of a minimum C0 has been reported to be most important
just before engraftment [2], it may bemost clinically relevant
to evaluate cyclosporine AUC when patients are receiving i.v.
cyclosporine.
The relationship between cyclosporine AUC after i.v.
administration and HSCT outcomes such as aGVHD is just
beginning to be explored [11,13,17-19,26,27]. Among these
are 2 pediatric studies. In the ﬁrst, Willemze et al. retro-
spectively estimated cyclosporine pharmacokinetic param-
eters including AUC in 91 children receiving i.v. cyclosporine
over 2 hours [19]. Cyclosporine concentrations were assayed
by either radioimmunoassay or ﬂuorescence polarization
immunoassay. No comment regarding the comparability of
the results of these assays was provided. AUC-12 was esti-
mated using Bayesian methods based primarily on C0 values
that the authors stated led to a potential error in AUC esti-
mations of approximately 20%. During the second week after
HSCT, AUC values greater than 3000 mg/L/h were associated
with lower overall survival rates and higher risk of relapse,
most especially in children with acute myelogenous
leukemia. No association between AUC and the incidence of
acute GVHD was observed.
Gerard et al. reported the second evaluation of cyclo-
sporine AUC in children undergoing HSCT [26]. In this retro-
spective analysis, cyclosporine AUC in blood and other tissues
were estimated using Bayesian models. The samplingTable 3
Bias and Precision of Estimates of AUC Using Limited Sampling Strategies for i.v. Cy
between Values of AUC Calculated Using All Data Points and Using the LSS
Sample Time
(hours from start
of 2-h infusion)
LSS Equation Adjusted r2
Validation of ﬁrst-dose LSS [20]
2, 6, and 8 1.429C2 þ 5.722C8 þ 2.741C6 þ 380.862 .965
2, 2.5, 6, and 8 1.372C2 þ 5.449C8 þ 2.870C6 þ .470C2.5 þ
165.709
.985
2, 2.5, 4, 6, and 8 1.229C2 þ 5.242C8 þ .740C6 þ .514C2.5 þ
2.7C4 þ 23.740
.993
Development of steady-state LSS
2, 2.5, and 8 1.22C2 þ 1.54C2.5 þ 8.26C8 þ 292 .9851
2, 2.5, 4, and 8 1.22C2 þ .78C2.5 þ 2.55C4 þ 5.91C8 þ 331 .9920
2, 2.5, 3, 4, and 8 1.26C2 þ 1.65C3 þ 2.43C4 þ 4.80C8 þ 261 .9967
Validation of steady-state LSS
2, 2.5, and 8 1.22C2 þ 1.54C2.5 þ 8.26C8 þ 292 .9875
2, 2.5, 4, and 8 1.22C2 þ .78C2.5 þ 2.55C4 þ 5.91C8 þ 331 .9937
2, 2.5, 3, 4, and 8 1.26C2 þ 1.65C3 þ 2.43C4 þ 4.80C8 þ 261 .9935
CI indicates conﬁdence interval.
An LSS was considered to provide an acceptable estimate of AUC-12 if the r2 value w
both bias and precision were 15% or less.schedule and the number of cyclosporine blood concentra-
tions available to inform the construction of the pharmaco-
kinetic model were not described. Children received
cyclosporine either as a continuous infusion (30 patients) or
as a 2-hour infusion every 12 hours (31 patients). Thirty-four
patients (56%) developed aGVHD. It was not clear if the
relationship between C0 and aGVHD occurrence was evalu-
ated. However, there was a signiﬁcant relationship between
cyclosporine AUC at steady state (deﬁned as the day before
the occurrence of aGVHD or day 13 after HSCT) and aGVHD.
For patients with underlying malignancy, the authors
concluded that cyclosporine doses be adjusted to achieve an
AUCof 10 hmg/L over 24hours (10,000 mg/L/h over 24hours;
5000 mg/L/h over 12 hours),which corresponds to a C2 andC12
of 1000 and 80 mg/L, respectively. It was furthermore sug-
gested that an AUC of 16 hmg/L over 24 hours (16,000 mg/L/h
over 24 hours; 8000 mg/L/h over 12 hours) corresponding
to a C2 and C12 of 1600 and 120 mg/L, respectively, be targeted
for patients without underlying malignancy.
The ﬁndings of these retrospective studies require
prospective validation before speciﬁc AUC values can be
adopted as the standard of care in clinical practice. The
availability of LSSs for estimation of cyclosporine AUC, such
as presented here, that can be performed without the use of
computer software will facilitate this process.
We found that the correlation between all data points and
AUC-12 was remarkably stronger in the steady-state LSS
validation cohort than in the other 3 study cohorts. Anotherclosporine Involving Fewer Than Five Data Points and Extent of Agreement
Mean Bias,
% (95% CI)
Precision (%) ICC (95% CI) Limits of
Agreement (%)
2.1 (.1-4.3) 5.0 .974 (.941 to .988) 13.4-8.9
2.5 (3.9-1.2) 3.2 .979 (.952-.991) 4.5-9.8
2.2 (2.9-1.4) 2.3 .994 (.985-.997) 1.7-6.1
.34 (2-1) 3.5 .984 (.965-.993) 7.2-7.3
.19 (1-1) 4.9 .994 (.986-.997) 4.6-4.3
.13 (0-1) 1.2 .995 (.988-.998) 2.9-2.9
3.5 (2-5) 3.3 .993 (.984-.997) 9.3-3.3
2.3 (1-3) 3.5 .996 (.991-.998) 7.3-2.7
1.7 (1-3) 1.4 .998 (.996-.999) 7.1-3.9
as> .9, lower limit of the 95% conﬁdence limit of the ICCwas .8 or higher, and
Table 4
Mean and Predicted AUC-12 Value Estimates Using the LSSs for Estimation
of Cyclosporine AUC Estimation after i.v. Administration over 2 Hours
Mean AUC-12 (SD) mg/L/h) 95% CI
Validation of ﬁrst-dose LSS
AUC-12 2509  672 2226-2793
Three point 2546  588 2297-2794
Four point 2431  595 2180-2682
Five point* 2480  671 2190-2770
Development of steady-state LSS
AUC-12 4888  1316 4279-5496
Three point 4865  1305 4262-5468
Four point 4940  1289 4424-5455
Five point 4935  1290 4419-5451
Validation of steady-state LSS
AUC-12 4200  1142 3746-4657
Three point 4324  1168 3856-4791
Four point 4282  1110 3837-4726
Five point 4255  1105 3813-4697
* n ¼ 23.
Figure 1. Bland-Altman plots. Percent difference against mean for actual
(AUC-12) and predicted area under the whole blood cyclosporine concentra-
tion versus time curve during 12-hour dosing interval generated by LSS.
Percent difference ¼ 100  [(AUC-12eAUC predicted by LSS)]/mean of AUC-12
and AUC predicted by LSS]. (A) First-dose 4-point LSS validation: % difference
against mean AUC. (B) Steady-state 3-point LSS development: % difference
against mean AUC. (C) Steady-state three-point LSS validation: % difference
against mean AUC.
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mycophenolate mofetil compared with the other 3 cohorts.
The potential inﬂuence of mycophenolate mofetil on cyclo-
sporine pharmacokinetic disposition has been identiﬁed
previously [28] and deserves further exploration.
For the purpose of this study, steady state was deﬁned as
having been achieved when patients had received at least 4
identical cyclosporine doses. Judging by the discrepant
correlations between C0 and the concentration 12 hours after
the start of the infusion (C12), true steady state likely was not
achieved in all patients. Indeed, the C0 and C12 differed
by > 20% in 6 (25%) and 4 patients (17%) in the development
and validation steady-state LSS cohorts, respectively.Fluctuations in dose times, infusion duration and/or rate,
liver function, and extent of enterohepatic circulation may
preclude achievement of steady state in HSCT patients in the
ﬁrst weeks after HSCT. Interpretation of our study ﬁndings
may also be limited by differences between cohorts such as
differences in aGVHD prophylaxis, pharmacogenetic poly-
morphism [29], and underlying diagnosis. Despite these
possible limitations, the proposed LSSs performed well in
estimating AUC-12 within each patient.
The LSSs developed and validated here permit conﬁdent
estimation of AUC-12 by clinicians. It must be noted that
their use is limited to the population in which they were
developed. That is, they may be used to estimate cyclo-
sporine AUC in children undergoing HSCTage .4 to< 18 years
of age and receiving cyclosporine as a 2-hour i.v. infusion.
Use of the 3-point ﬁrst-dose (2, 6, and 8 hours) and steady-
state (2, 2.5, and 8 hours) LSSs to prospectively evaluate
the relationship between cyclosporine AUC and HSCT
outcomes in children is suggested.
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